Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer: Results from a phase 1/2 study.

医学 内科学 肺癌 肿瘤科 队列 临床研究阶段 癌症 临床试验 肺 抗体 毒性 不利影响 外科 疾病 中止 安全概况 临床终点 实体瘤疗效评价标准 第一行 免疫疗法 靶向治疗 人口 胃肠病学 阶段(地层学) 进行性疾病 化疗
作者
Wei Li,L G Sun,Yan Yu,Sanxing Guo,Jian Fang,Bo Gao,Peng Zhang,Jianhua Shi,Huang Yun-jian,Haifeng Liu,X C Dong,Wenxiu Yao,Jingru Wang,Qiang Wang,Teng Fang,Bo Wang,Hangjun Dai,Qingmei Shi,Jason Yang,Caicun Zhou
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl): 8558-8558
标识
DOI:10.1200/jco.2026.44.16_suppl.8558
摘要

8558 Background: CS2009 is a novel PD-1/VEGF/CTLA-4 trispecific antibody. An ongoing phase 1/2 study is evaluating its safety, tolerability, PK, PD, and anti-tumor activity as a single agent and in combination with systemic treatment in patients (pts) with advanced solid tumors. This study comprises a phase 1 dose escalation and phase 2 dose expansion. Here, we report the initial efficacy and safety data from advanced non-small cell lung cancer (NSCLC) pts treated in first-line and later-line settings. Methods: The study enrolled both treatment-naïve (1L) and heavily pre-treated later-line (≥2L) NSCLC pts. The ≥2L group included previously treated pts without known actionable oncogenic alterations (AGA) who had progressed on at least one prior line containing an anti-PD-1/L1 antibody and platinum-based chemotherapy; these pts received CS2009 at 10, 20, 30, or 45 mg/kg, i.v., Q3W, until disease progression or intolerance. The 1L cohort enrolled treatment-naïve pts with PD-L1 TPS ≥1% NSCLC without known AGA; these pts were randomized 1:1 to receive CS2009 at 20 or 30 mg/kg, i.v., Q3W, until disease progression or intolerance. Safety was assessed in all treated pts. Efficacy was assessed in pts who had at least one post-baseline tumor assessment per RECIST v1.1. Results: As of Jan. 4, 2026, 40 pts with ≥2L NSCLC were treated with CS2009 across four dose levels (10 mg/kg, n=3; 20 mg/kg, n=12; 30 mg/kg, n=20; 45 mg/kg, n=5). Median age was 67 (range 37-78) years; 72.5% were Asian, 27.5% were White; 77.5% were male; 77.5% had ECOG PS 1 at baseline. Among 30 efficacy-evaluable pts, ORR was 20.0% (6 PRs); in 16 pts treated at 30 mg/kg, ORR was 25.0% (4 PRs). Any-grade and grade ≥3 treatment-related adverse events (TRAEs) occurred in 27 (67.5%) and 8 (20.0%) pts, respectively. The most common TRAEs were proteinuria (12.5%), hypertension (12.5%), bilirubin conjugated increased (10.0%), and fatigue (10.0%), which were mostly grade 1 or 2, except for grade ≥3 hypertension in two pts. No treatment-related deaths were reported. TRAEs led to discontinuation in 3 (7.5%) pts. More mature ≥2L efficacy data with additional evaluable pts will be presented at the conference. As of Jan. 4, 2026, 19 pts with 1L NSCLC (PD-L1 TPS ≥1%) were randomized to receive CS2009 at 20 mg/kg (n=10) or 30 mg/kg (n=9). Median age was 69 (range 52-82) years; 84.2% were male; 89.5% had ECOG PS 1 at baseline. Preliminary encouraging efficacy and favorable safety signals were observed. Updated efficacy and safety data in approximately 50 1L pts will be disclosed at the conference. Conclusions: CS2009, as a first-in-class trispecific antibody targeting PD-1, VEGF, and CTLA-4, demonstrated a favorable safety profile and clinically meaningful anti-tumor activity in advanced NSCLC pts without known AGA. These findings warrant further investigation of CS2009 in this population. Clinical trial information: NCT06741644 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
东风完成签到,获得积分10
刚刚
look完成签到 ,获得积分10
1秒前
1秒前
TangDing完成签到,获得积分10
1秒前
沟通亿心完成签到,获得积分10
1秒前
Serein发布了新的文献求助10
2秒前
帅气寒松完成签到,获得积分10
2秒前
dd完成签到 ,获得积分10
2秒前
2秒前
哦莫完成签到 ,获得积分10
2秒前
异氰酸正丙酯完成签到 ,获得积分10
3秒前
晚塬完成签到 ,获得积分10
3秒前
等待的鸡翅完成签到,获得积分10
3秒前
瘦瘦滢发布了新的文献求助10
3秒前
SmileLin发布了新的文献求助10
4秒前
chunfengfusu的应助被不穷知识采纳,获得10
4秒前
指鹿为马完成签到,获得积分10
4秒前
年年完成签到,获得积分10
4秒前
小白鼠完成签到 ,获得积分10
5秒前
facemask完成签到,获得积分10
5秒前
山沟沟完成签到,获得积分10
5秒前
5秒前
秋月明完成签到,获得积分10
5秒前
伍安发布了新的文献求助10
5秒前
tuzi完成签到,获得积分0
5秒前
秋风的应助被NiaoJiang采纳,获得10
5秒前
阿信的一颗苹果完成签到 ,获得积分10
6秒前
潘雨露完成签到,获得积分10
6秒前
狂野水壶完成签到 ,获得积分10
6秒前
青竹完成签到,获得积分10
6秒前
机灵南风完成签到,获得积分10
7秒前
tszjw168发布了新的文献求助10
7秒前
灵巧的青寒完成签到,获得积分10
8秒前
奶蛙完成签到 ,获得积分10
8秒前
8秒前
飞快的邴完成签到,获得积分10
8秒前
二三完成签到 ,获得积分10
8秒前
习惯完成签到,获得积分20
8秒前
田様的应助被MongMong采纳,获得10
8秒前
HAHAHA完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039